FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx

January 11, 2024

https://www.globenewswire.com/news-release/2024/01/11/2808325/7281/en/FDA-Acceptance-of-Zevra-s-Arimoclomol-NDA-Filing-for-Niemann-Pick-Disease-Type-C-NPC-Results-in-XOMA-Making-a-1-Million-Milestone-Payment-to-LadRx.html

EMERYVILLE, Calif., Jan. 11, 2024 (GLOBE NEWSWIRE) — XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today that based upon the U.S. Food and Drug Administration’s (FDA) acceptance of Zevra Therapeutics’ New Drug Application (NDA) for arimoclomol, an orally-delivered, first-in-class therapy for Niemann-Pick disease type C (NPC), XOMA will make a $1 million milestone payment to LadRx.

Read more at globenewswire.com

Related news for (XOMA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.